Fo­cused on PhI­II, BeiGene touts ear­ly PD-1 re­sults; Am­gen part­ners with Sim­cere on Chi­na biosim­i­lars work

→ Hus­tling as fast as it can, BeiGene $BGNE to­day of­fered an ear­ly look at ear­ly-stage da­ta for its PD-1 check­point part­nered with Cel­gene $CELG. The com­pa­ny says it got the ini­tial tu­mor re­spons­es it was look­ing for — with no dose-lim­it­ing tox­i­c­i­ty — as re­searchers pur­sue two reg­is­tra­tion stud­ies for BGB-A317 in urothe­lial can­cer and clas­si­cal Hodgkin lym­phoma. The Chi­na-based biotech has a slate of Phase III stud­ies in the pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER